Replies: 3 comments 2 replies
-
This query is one that I proposed and envisioned as an AOP or Adverse Outcome Pathway, with DILI or drug-induced liver injury serving as an example 'disease'. However, the query itself has applicability to any disease or drug/chemical-related adverse outcome. Here are a few additional thoughts that I included with my proposal: Given a disease, find genes, sequence variants, and/or biological processes that contribute to the disease or manifestation of disease or severity/chronicity of disease. Considerations: new predicate, could be qualified (e.g., severity, chronicity), use of underrepresented/underused Biolink category/entity type (biolink:SequenceVariant, biolink:BiologicalProcess), ‘ground truth’ or suspected genes are established for DILI (HLA-1, HLA-II, ERAP2, EXOCYST4 [EXOCYST3], PTPN22). |
Beta Was this translation helpful? Give feedback.
-
@marcdubybroad @bill-baumgartner : From what I gathered during today's TAQA call (and I admittedly didn't hear everything, as I stepped out for a few minutes), it sounds like both of your KPs will be able to contribute knowledge on both genes and variants to MVP#3. Is that correct? |
Beta Was this translation helpful? Give feedback.
-
Great! Thanks for the updates, Bill and Marc. I knew about the unqualified gene-disease data, but I was not aware of the qualified variant data. |
Beta Was this translation helpful? Give feedback.
-
This discussion thread is intended to promote discussion among the TCDC regarding the MVP#2 templated query and approaches for incorporating clinical knowledge into inferred (creative) mode responses:
What {gene, sequence variant, biological process} [contributes to] [disease]?
Beta Was this translation helpful? Give feedback.
All reactions